Clinical trial
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV…
NCT00091286 · Craig L Slingluff, Jr, Other · Terminated
Key facts
| NCT number | NCT00091286 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer |
| Official title | Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer |
| Lead sponsor | Craig L Slingluff, Jr, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological |
| Interventions | HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine |
| Enrollment | 11 |
| Start date | Mar 24, 2003 |
| Primary completion | Feb 15, 2008 |
| Completion | Feb 15, 2008 |
| First posted | Sep 9, 2004 |
| Last update posted | Mar 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: